A large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).
Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancer retrieved 4 June 2024 from https://medicalxpress.com/news/2024-06-phase-iii-trial-lorlatinib-highly.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Doctors develop minimally invasive procedure to avoid drilling a 'burr hole' in the skull to treat clot on the brainUse this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Phase III trial shows donidalorsen cuts attack rate in hereditary angioedemaFor patients with hereditary angioedema, donidalorsen reduces the attack rate, according to a study published online May 31 in the New England Journal of Medicine to coincide with the annual congress of the European Academy of Allergy and Clinical Immunology, held from May 31 to June 3 in Valencia, Spain.
Read more »
Proton therapy demonstrates advantages over traditional radiation therapy in Phase III head and neck cancer trialAccording to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy (IMRT) as part of...
Read more »
Perioperative immunotherapy significantly improves event-free survival in patients with resectable NSCLCCompared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer(NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Read more »
Phase 1 trial for EBC-129 progresses into dose expansionThe Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.
Read more »
Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammationChronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.
Read more »
Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trialClinicians at Georgetown University's Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).
Read more »